Download Sample
Add to CartGlobal Lower GI Series Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Procedure;
Single-Contrast Imaging and Double-Contrast ImagingBy Product Type;
Contrast Media, Imaging Equipment, Consumables, and AccessoriesBy Applications;
Gastroenteritis, Colon Polyps, Tumor, Strictures Crohn's Disease, Ulcerative Colitis and OthersBy End User;
Hospitals and Clinics & LaboratoriesBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031)Lower GI Series Market Overview
Lower GI Series Market (USD Million)
Lower GI Series Market was valued at USD 242.19 million in the year 2024. The size of this market is expected to increase to USD 384.70 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.8%.
Global Lower GI Series Market Growth, Share, Size, Trends and Forecast
*Market size in USD million
CAGR 6.8 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 6.8 % |
| Market Size (2024) | USD 242.19 Million |
| Market Size (2031) | USD 384.70 Million |
| Market Concentration | Medium |
| Report Pages | 366 |
Major Players
- GE Healthcare
- Siemens Healthineers
- Philips Healthcare
- Hitachi Healthcare
- Shimadzu Corporation
- Toshiba Medical Systems Corporation
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Global Lower GI Series Market
Fragmented - Highly competitive market without dominant players
The Lower GI Series Market is gaining traction due to the growing reliance on diagnostic imaging to identify large intestine disorders. Lower gastrointestinal (GI) series, or barium enema tests, play a pivotal role in detecting colorectal cancer, diverticulitis, and other intestinal issues. With over 25% of GI-related conditions linked to the lower tract, demand for precise and reliable diagnostic tools is expanding steadily.
Improved Imaging Capabilities and Workflow Efficiency
Ongoing improvements in imaging systems are enhancing the effectiveness and efficiency of lower GI series procedures. Enhanced contrast imaging and digital radiographic systems have contributed to a 20% boost in diagnostic accuracy. These advancements are not only increasing clinician confidence but also reducing the need for follow-up procedures.
Preventive Screening Trends and Patient Awareness
Greater awareness around preventive screening and early diagnosis has positively impacted the adoption of lower GI series. Around 35% of gastrointestinal screenings now incorporate these procedures as part of routine health assessments. The growing patient engagement in proactive healthcare is supporting this upward trend.
Policy Initiatives and Institutional Adoption
Government support and clinical standardization are further driving the integration of lower GI series into diagnostic practices. Over 40% of healthcare facilities now use these tests as part of routine evaluations for intestinal disorders. The market is benefiting from this increased institutional acceptance and supportive regulatory environment.
Lower GI Series Market Recent Developments
- In January 2024, Boston Scientific launched the new Flex-AX Arthroscope to improve visualization during colonoscopies.
- In February 2024, Capital Digestive Care merged with GI Alliance to form a leading GI provider network.
- In March 2024, Iterative Scopes received FDA approval for its AI-powered colonoscopy platform, enhancing polyp detection.
Lower GI Series Market Segment Analysis
In this report, the Lower GI Series Market has been segmented by Procedure, Product Type, Applications, End User and Geography.
Lower GI Series Market, Segmentation by Procedure
The Lower GI Series Market has been segmented by Procedure into Single-contrast Imaging and Double-contrast Imaging.
Single-contrast Imaging
Single-contrast imaging is one of the foundational procedures in the lower gastrointestinal (GI) series market. This method uses a contrast agent—typically barium sulfate—introduced into the colon to outline the GI tract on radiographic images. It is particularly effective in detecting major abnormalities like blockages, strictures, and sizable tumors. This technique is frequently chosen for its efficiency, ease of administration, and patient tolerance, especially among elderly or critically ill patients. Roughly 55% of lower GI series procedures worldwide use single-contrast imaging, underlining its prevalence due to affordability and straightforward implementation.
Double-contrast Imaging
Double-contrast imaging stands out for its enhanced diagnostic accuracy. By using both a contrast medium and air, this technique offers a detailed view of the intestinal mucosa, making it ideal for identifying small polyps, early-stage cancers, and subtle mucosal changes. Although it requires more preparation and time, the superior clarity of images makes this method increasingly popular, especially in advanced clinical settings. It constitutes around 45% of global procedures and is steadily gaining preference among specialists seeking more precise evaluations.
Lower GI Series Market, Segmentation by Product Type
The Lower GI Series Market has been segmented by Product Type into Contrast Media, Imaging Equipment, Consumables, and Accessories.
Contrast Media
Contrast media are critical components in lower gastrointestinal (GI) diagnostic procedures. These substances, primarily barium sulfate, are used to enhance the visibility of the intestinal tract during imaging. With their ability to significantly improve diagnostic accuracy, contrast agents are integral to both single-contrast and double-contrast techniques. This segment holds a dominant position, accounting for about 40% of the global market share. As routine colorectal screenings and early diagnosis initiatives increase globally, the demand for effective contrast media continues to grow steadily.
Imaging Equipment
The imaging equipment segment includes vital tools such as X-ray systems, fluoroscopy machines, and digital radiography units, which serve as the core infrastructure for conducting lower GI procedures. This category contributes approximately 30% to the market. With rapid technological advancements and growing healthcare digitization, the uptake of modern imaging systems is particularly high in developed countries. Improved image resolution, reduced radiation exposure, and greater diagnostic speed are key factors driving investment in this segment.
Consumables
Consumables include essential single-use items like catheters, tubing, and enema kits that ensure safe and hygienic administration of lower GI procedures. These products, while lower in cost, are required in every procedure, supporting a continuous demand cycle. The consumables segment comprises around 20% of the overall market. With rising procedure volumes, particularly in preventive screening programs, this segment plays a significant role in the operational side of diagnostics.
Accessories
The accessories segment includes supporting tools such as patient positioning aids, gowns, and preparation kits, which enhance both patient comfort and procedural workflow. Although it represents a smaller share—about 10% of the total market—this segment is vital for maintaining a quality care experience. With healthcare settings placing more emphasis on patient-centric care and infection control, demand for such accessories remains consistent.
Lower GI Series Market, Segmentation by Applications
The Lower GI Series Market has been segmented by Applications into Gastroenteritis, Colon Polyps, Tumor, Strictures Crohn's Disease, Ulcerative Colitis and Others.
Gastroenteritis and Colon Polyps
Gastroenteritis is a leading condition evaluated through lower gastrointestinal (GI) series procedures, accounting for approximately 25% of global application usage. Characterized by inflammation of the stomach and intestines, this condition often requires diagnostic imaging to detect complications or rule out more serious diseases. In parallel, colon polyps represent about 20% of the application share. Since these polyps can evolve into colorectal cancer if left untreated, early detection through lower GI series plays a crucial role in preventive healthcare and routine screening programs.
Tumors and Strictures
The detection of tumors within the colon is a vital application of lower GI series imaging, representing roughly 18% of the market. These imaging techniques help physicians evaluate the location, size, and potential spread of abnormal growths, aiding in timely diagnosis and treatment planning. Strictures, which refer to the narrowing of intestinal passages, account for around 15%. These conditions can lead to obstructive symptoms and require clear imaging to guide clinical interventions. The detailed visualization provided by contrast-enhanced imaging is especially beneficial in these scenarios.
Crohn’s Disease and Ulcerative Colitis
Chronic inflammatory conditions like Crohn’s disease and ulcerative colitis also utilize lower GI imaging for ongoing management. Crohn’s disease holds a market share of about 10%, primarily affecting patients in developed regions. Ulcerative colitis, another form of inflammatory bowel disease, contributes approximately 7% to the application spectrum. These disorders often require repeated imaging to monitor disease progression, evaluate treatment response, and prevent complications, making lower GI series an important diagnostic support tool.
Others
The “Others” category covers a diverse range of lesser-known applications, including post-surgical follow-ups, rare intestinal disorders, and miscellaneous gastrointestinal issues. Though this segment constitutes just 5% of the market, it emphasizes the versatility and clinical utility of lower GI series imaging across various diagnostic needs.
Lower GI Series Market, Segmentation by End User
The Lower GI Series Market has been segmented by End User into Hospitals and Clinics & Laboratories.
Hospitals
Hospitals are the dominant end users in the lower gastrointestinal (GI) series market, accounting for approximately 65% of the total market. This segment benefits from comprehensive infrastructure, including advanced imaging equipment, experienced radiology staff, and the capacity to manage a large volume of patients. Lower GI series procedures are commonly used in hospital settings for the diagnosis of conditions such as colorectal tumors, strictures, and inflammatory bowel diseases. The integration of imaging systems with electronic health records enhances diagnostic accuracy and workflow efficiency, making hospitals the primary centers for gastrointestinal imaging.
Clinics
Clinics, including outpatient and specialty diagnostic centers, hold a market share of around 20%. These facilities are increasingly adopting portable and cost-effective imaging technologies that allow them to perform lower GI series procedures efficiently. Clinics are ideal for routine screenings and preventive care, especially for conditions like colon polyps or gastroenteritis. Their ability to offer convenient appointment scheduling and faster results makes them a preferred choice for patients looking for non-emergency GI assessments.
Laboratories
Laboratories contribute approximately 15% to the lower GI series market and typically support both hospitals and clinics. These labs may either house in-house imaging capabilities or collaborate with external imaging providers to deliver diagnostic reporting, image analysis, and data management services. As the trend toward diagnostic outsourcing
Lower GI Series Market, Segmentation by Geography
In this report, the Lower GI Series Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Regions and Countries Analyzed in this Report
Lower GI Series Market Share (%), by Geographical Region, 2024
North America
North America dominates the lower gastrointestinal (GI) series market, accounting for an estimated 35% of the total share. This leadership position is supported by advanced healthcare systems, a high prevalence of gastrointestinal conditions, and robust screening programs for colorectal cancer. The United States and Canada benefit from widespread use of state-of-the-art imaging technologies, strong insurance coverage, and active government support for preventive care. Ongoing clinical research and technological innovation further enhance market momentum in the region.
Europe
With a market share of around 25%, Europe is the second-largest regional contributor to the lower GI series market. Countries such as Germany, France, and the United Kingdom have made significant investments in early diagnosis and screening programs, particularly for colorectal and inflammatory bowel diseases. The presence of leading medical imaging manufacturers and a focus on public health awareness contribute to steady demand. Supportive healthcare policies and government-funded diagnostic initiatives play a key role in expanding access.
Asia Pacific
The Asia Pacific region is experiencing rapid growth and currently accounts for nearly 20% of the global market. Emerging economies like China, India, and Indonesia are witnessing a surge in demand for GI diagnostics due to increasing healthcare expenditure and rising disease prevalence. Improvements in healthcare infrastructure, along with a growing middle-class population, are creating new opportunities. However, disparities in rural healthcare access and affordability still present challenges in realizing the full market potential.
Middle East and Africa & Latin America
Together, the Middle East and Africa and Latin America contribute about 20% to the global market, with each region representing roughly 10%. In the Middle East, nations like Saudi Arabia and the UAE are investing in modern diagnostic capabilities, while public-private partnerships support growth. In Latin America, countries like Brazil and Mexico are prioritizing healthcare expansion and screening initiatives. Though both regions face limitations in infrastructure and accessibility, ongoing development and awareness campaigns are steadily advancing market penetration.
Lower GI Series Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Lower GI Series Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Comprehensive Market Impact Matrix
This matrix outlines how core market forces—Drivers, Restraints, and Opportunities—affect key business dimensions including Growth, Competition, Customer Behavior, Regulation, and Innovation.
| Market Forces ↓ / Impact Areas → | Market Growth Rate | Competitive Landscape | Customer Behavior | Regulatory Influence | Innovation Potential |
|---|---|---|---|---|---|
| Drivers | High impact (e.g., tech adoption, rising demand) | Encourages new entrants and fosters expansion | Increases usage and enhances demand elasticity | Often aligns with progressive policy trends | Fuels R&D initiatives and product development |
| Restraints | Slows growth (e.g., high costs, supply chain issues) | Raises entry barriers and may drive market consolidation | Deters consumption due to friction or low awareness | Introduces compliance hurdles and regulatory risks | Limits innovation appetite and risk tolerance |
| Opportunities | Unlocks new segments or untapped geographies | Creates white space for innovation and M&A | Opens new use cases and shifts consumer preferences | Policy shifts may offer strategic advantages | Sparks disruptive innovation and strategic alliances |
Drivers, Restraints and Opportunity Analysis
Drivers
- Increasing Incidence of Gastrointestinal Disorders
- Growing Aging Population
- Advancements in Imaging Technology
- Rising Awareness and Screening Initiatives for Colorectal Cancer
-
Demand for Early and Accurate Diagnosis - The increasing need for early and precise diagnosis is significantly driving the growth of the lower GI series market, as medical practitioners aim to detect gastrointestinal conditions at earlier stages to improve outcomes. Timely identification of issues such as colorectal cancer, inflammatory bowel disease, and diverticulitis enables more effective intervention and helps minimize the progression of serious complications. The lower GI series offers detailed visualization of the large intestine, allowing for the detection of structural irregularities that might be missed with more generalized imaging techniques.
As awareness surrounding digestive health continues to grow and the global burden of gastrointestinal disorders rises, healthcare providers are increasingly relying on accurate, accessible diagnostic tools. The lower GI series is emerging as a preferred method in screening and diagnostic routines, particularly for high-risk groups. Its ability to deliver reliable insights into the lower gastrointestinal tract supports its expanding adoption across hospitals and diagnostic centers, making it a crucial component in improving clinical decision-making and enhancing patient outcomes.
Restraints
- High Cost of Imaging Equipment and Procedures
- Radiation Exposure Risks
- Limited Access to Healthcare Facilities in Developing Regions
- Alternative Diagnostic Modalities
-
Reimbursement Challenges - Reimbursement limitations continue to pose a significant restraint on the lower GI series market, as many healthcare systems offer partial or inconsistent coverage for this diagnostic procedure. Patients often face high out-of-pocket costs when insurance providers prioritize alternative imaging methods or impose strict eligibility criteria. This financial burden discourages timely diagnostic evaluations, particularly among low- to middle-income populations, thereby limiting the widespread use of lower GI series for early detection of gastrointestinal disorders.
Healthcare providers also encounter operational challenges due to unpredictable or inadequate reimbursement structures, which can reduce incentives to recommend or invest in lower GI imaging capabilities. The absence of uniform reimbursement policies across countries—and even within regions—further complicates the market landscape. These economic and administrative hurdles slow the adoption of an otherwise valuable diagnostic tool, curbing its role in enhancing preventive care, early diagnosis, and overall gastrointestinal health management.
Opportunities
- Emerging Markets with Untapped Growth Potential
- Technological Innovations in Imaging Modalities
- Integration of Artificial Intelligence in Image Analysis
- Shift Towards Minimally Invasive Diagnostic Procedures
-
Collaborations and Partnerships for Market Expansion - The growing emphasis on collaborations and partnerships is unlocking new opportunities for the lower GI series market, particularly in enhancing access to diagnostic technologies and expanding clinical capabilities. Strategic alliances between hospitals, diagnostic centers, imaging equipment manufacturers, and healthcare providers are facilitating the integration of lower GI series into broader diagnostic frameworks. These partnerships often lead to shared expertise, resource pooling, and streamlined workflows, helping healthcare facilities deliver more comprehensive gastrointestinal care.
Collaborations with public health agencies and non-profit organizations are also playing a crucial role in improving awareness, screening outreach, and infrastructure development in underserved regions. By joining forces, stakeholders can overcome logistical and financial barriers, expanding the reach of lower GI diagnostic services in both urban and rural settings. Such initiatives not only help identify gastrointestinal conditions at an earlier stage but also contribute to reduced disease burden and improved health outcomes at the population level.
In the private sector, industry partnerships are driving innovation through joint R&D efforts aimed at enhancing imaging accuracy, reducing radiation exposure, and developing more patient-friendly contrast agents. These collaborations accelerate the availability of next-generation solutions while ensuring compliance with evolving regulatory standards. By investing in co-development models, companies can also benefit from faster market penetration and a more diversified product portfolio.
As global healthcare systems prioritize efficiency and patient-centered care, collaborative strategies are becoming a key enabler of growth in the lower GI series market. These alliances not only strengthen diagnostic networks but also foster the exchange of best practices, ultimately improving clinical outcomes and creating a more scalable and sustainable healthcare delivery model.
Lower GI Series Market Competitive Landscape Analysis
Key players in Lower GI Series Market include,
- Allied Digestive Health
- Boston Scientific
- Capital Digestive Care
- CRH Medical
- Iterative Scopes
- Fujifilm Medical
- Gastro Health
- GI Alliance
- Medtronic
- Micro-Tech Endoscopy
- Motus GI
- Olympus
- One GI
- PE GI Solutions
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Market Share Analysis
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Procedure
- Market Snapshot, By Product Type
- Market Snapshot, By Applications
- Market Snapshot, By End User
- Market Snapshot, By Region
- Lower GI Series Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing Incidence of Gastrointestinal Disorders
- Growing Aging Population
- Advancements in Imaging Technology
- Rising Awareness and Screening Initiatives for Colorectal Cancer
- Demand for Early and Accurate Diagnosis
- Restraints
- High Cost of Imaging Equipment and Procedures
- Radiation Exposure Risks
- Limited Access to Healthcare Facilities in Developing Regions
- Alternative Diagnostic Modalities
- Reimbursement Challenges
- Opportunities
- Emerging Markets with Untapped Growth Potential
- Technological Innovations in Imaging Modalities
- Integration of Artificial Intelligence in Image Analysis
- Shift Towards Minimally Invasive Diagnostic Procedures
- Collaborations and Partnerships for Market Expansion
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Lower GI Series Market, By Procedure, 2021 - 2031 (USD Million)
- Single-contrast Imaging
- Double-contrast Imaging
- Lower GI Series Market, By Product Type, 2021 - 2031 (USD Million)
- Contrast Media
- Imaging Equipment
- Consumables
- Accessories
- Lower GI Series Market, By Applications, 2021 - 2031 (USD Million)
- Gastroenteritis
- Colon Polyps
- Tumor
- Strictures Crohn's Disease
- Ulcerative Colitis
- Others
- Lower GI Series Market, By End User, 2021 - 2031 (USD Million)
- Hospitals
- Clinics & Laboratories
- Lower GI Series Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN(Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Lower GI Series Market, By Procedure, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Allied Digestive Health
- Boston Scientific
- Capital Digestive Care
- CRH Medical
- Iterative Scopes
- Fujifilm Medical
- Gastro Health
- GI Alliance
- Medtronic
- Micro-Tech Endoscopy
- Motus GI
- Olympus
- One GI
- PE GI Solutions
- Company Profiles
- Analyst Views
- Future Outlook of the Market